| 1. |
1 Schunemann HJ, Cook D, Guyatt G. Methodology for antithrombotic and thrombolytic therapy guideline development: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition).
Chest , 2008, 133(6 Suppl): 113S-122S.
|
| 2. |
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet , 1997.
|
| 3. |
Letelier LM, Udol K, Ena J, et al . Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med , 2003, 163(7): 777-785.
|
| 4. |
Guyatt G, Oxman AD, Kunz R, et al . Grade Guidelines: 6. Rating the quality of evidence: Inconsistency. Journal of Clnical Epidemiology , 2010.
|
| 5. |
Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet , 2008, 371(9624): 1559-1561.
|
| 6. |
Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol , 2002, 31(1): 72-76.
|
| 7. |
Schmid, CH, Lau J, Mcintosh MW, et al . An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med , 1998, 17(17): 1923-1942.
|
| 8. |
Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med , 2002, 21(11): 1575-1600.
|
| 9. |
Singer DE, Albers GW, Dalen JE, et al . Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest , 2008, 133(6 Suppl): 546S-592S.
|
| 10. |
Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med , 1998, 128(2): 89-95.
|
| 11. |
Bischoff-Ferrari HA, Willett WC, Wong JB, et al . Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA , 2005, 293(18): 2257-2264.
|
| 12. |
Montori VM, Gandhi GY, Guyatt GH. Patient-important outcomes in diabetes--time for consensus. Lancet , 2007, 370(9593): 1104-1106.
|
| 13. |
Gandhi GY. Murad MH, Fujiyoshi A, et al . Patient-important outcomes in registered diabetes trials. JAMA , 2008, 299(21): 2543-2549.
|
| 14. |
Bucher H, Guyatt G, Cook D, et al . Surrogate outcomes. In: Guyatt G, et al, editors. The users’ guides to the medical literature: a manual for evidence-based clinical practice. New York, NY: McGraw-Hill; 2008.
|
| 15. |
Lasser KE, Allen PD, Woolhandler SJ, et al . Timing of new black box warnings and withdrawals for prescription medications. JAMA , 2002, 287(17): 2215-2220.
|
| 16. |
Bowker SL, Majumdar SR, Veugelers P, et al . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care , 2006, 29(2): 254-258.
|
